We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




MRI Contrast Agents Not Associated with Parkinson’s Disease

By MedImaging International staff writers
Posted on 21 Jul 2016
Print article
Image: Gadovist, a gadolinium-based contrast agent (Photo courtesy of Bayer).
Image: Gadovist, a gadolinium-based contrast agent (Photo courtesy of Bayer).
A new study found no connection between gadolinium exposure and Parkinson’s disease (PD), a degenerative disorder characterized by tremor and impaired muscular coordination.

Researchers at Researchers at Western University (WU; London, Canada) reviewed multiple linked administrative databases from Ontario (Canada) that included 246,557 patients older than 66 years who underwent at least one magnetic resonance imaging (MRI) scan between April 2003 and March 2013. Patients who were exposed to gadolinium-enhanced MRIs were compared with patients who received non-gadolinium-enhanced MRIs. MRI scans of the brain or spine were excluded.

The study found that 40.5% of the study patients received at least one dose of a gadolinium-based contrast agent (GBCA), with 81.5% undergoing a single study, and 2.5% receiving four or more GBCA-enhanced studies. In all, incident Parkinsonism developed in 1.2% of unexposed patients, and an equal 1.2% developed in those exposed to gadolinium. The study was published on July 5, 2016, in JAMA.

“Gadolinium-based contrast agents are used for enhancement during MRI; safety concerns have emerged over retained gadolinium in the globus pallidi,” concluded lead author Blayne Welk, MD, MSc, of Western University, and colleagues. “This result does not support the hypothesis that gadolinium deposits in the globus pallidi lead to neuronal damage manifesting as Parkinsonism. However, reports of other nonspecific symptoms) after gadolinium exposure require further study.”

Gadolinium--a rare earth heavy metal--is used for enhancement during MRI. Neurotoxic effects have been seen in animals, and when a GBCA is given intrathecally in humans. In July 2015, the U.S. Food and Drug Administration (FDA) stated that it was unknown whether gadolinium deposits in the globus pallidi, a subcortical structure of the brain, were harmful. The globus pallidus is a major component of the basal ganglia core along with the striatum and its direct target, the substantia nigra, and also retains close functional ties with the subthalamus, all part of the extrapyramidal motor system.

Related Links:
Western University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Digital Radiography Acquisition Software
VXvue with PureImpact
Ultrasound System
P25 Elite
New
Oncology Information System
RayCare

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.